suPAR – Biomarker for Inflammation and Immune Status

What Is suPAR?

suPAR stands for soluble urokinase-type plasminogen activator receptor. It is a protein that can be measured in blood, urine, and other body fluids, and serves as a biomarker for immune system activation, inflammation, and tissue remodeling. suPAR is released into the bloodstream by various immune cells, including monocytes, neutrophils, and endothelial cells.

As a biomarker, suPAR reflects how strongly a person's immune system is activated. Higher suPAR levels generally indicate a stronger immune or inflammatory response in the body.

Biological Function

The membrane-bound form of this protein, urokinase-type plasminogen activator receptor (uPAR), plays an important role in several biological processes:

• Cell adhesion and migration: uPAR supports the movement of cells through tissue, which is essential for wound healing and immune defense.
• Tissue remodeling: The protein is involved in the breakdown of fibrous structures (fibrinolysis).
• Angiogenesis: It promotes the formation of new blood vessels.
• Inflammation regulation: uPAR coordinates signaling pathways that modulate inflammatory responses.

When uPAR is cleaved from the cell surface, the resulting soluble suPAR is released and can be detected in blood, urine, and cerebrospinal fluid.

Clinical Significance as a Biomarker

suPAR has become an established biomarker in both medical research and clinical practice. Elevated suPAR levels are observed in a wide range of conditions:

Infections and Sepsis

In cases of infection and sepsis (a life-threatening systemic inflammatory response to infection), suPAR levels rise significantly. Studies show that suPAR can help assess the severity of sepsis and predict patient outcomes. Very high suPAR levels are associated with increased risk of mortality.

Cardiovascular Diseases

Elevated suPAR levels are linked to an increased risk of heart attack, heart failure, and atherosclerosis. suPAR is therefore being investigated as a potential predictive biomarker for cardiovascular events.

Kidney Diseases

suPAR has gained particular attention in focal segmental glomerulosclerosis (FSGS), a form of kidney disease. Evidence suggests that circulating suPAR may directly contribute to damage of kidney podocytes (specialized kidney cells) and has been discussed as a potential trigger of this condition.

COVID-19

During the COVID-19 pandemic, elevated suPAR levels in COVID-19 patients were found to be associated with more severe disease and a higher likelihood of requiring intensive care. Clinical studies investigated suPAR as an early risk stratification marker.

Chronic Inflammatory and Autoimmune Diseases

In conditions such as rheumatoid arthritis and systemic lupus erythematosus, suPAR levels are frequently elevated and reflect ongoing inflammatory activity.

Oncology (Cancer)

In cancer research, suPAR is being explored as a potential tumor marker. Elevated levels have been observed in various cancer types, as tumor cells can upregulate uPAR expression to facilitate invasive growth.

Measurement of suPAR

suPAR is typically measured using an ELISA assay (Enzyme-linked Immunosorbent Assay) from a blood sample. Measurement can also be performed in urine or cerebrospinal fluid. In healthy adults, normal suPAR levels are generally below 3 ng/ml, though exact reference ranges may vary depending on the laboratory and test method used.

• Normal range: below 3 ng/ml (healthy adults)
• Mildly elevated: 3–6 ng/ml (may indicate chronic inflammation)
• Significantly elevated: above 6 ng/ml (associated with severe disease and increased mortality risk)

Advantages Over Other Inflammatory Markers

Compared to classic inflammatory markers such as C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR), suPAR has some distinctive characteristics:

• suPAR changes more slowly and reflects the medium-term immune status, not just an acute inflammatory reaction.
• It is less influenced by short-term factors such as minor infections or physical exertion.
• suPAR can be used as a prognostic marker to estimate long-term disease course.

Limitations and Ongoing Research

Despite its promising properties, suPAR as a biomarker is not disease-specific – elevated values can point to many different conditions. Therefore, suPAR is generally interpreted not in isolation, but in combination with other clinical parameters and laboratory values. Research is ongoing to further define the diagnostic and therapeutic utility of suPAR in clinical settings.

References

1. Eugen-Olsen J et al. - The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Journal of Infectious Diseases, 1997.
2. Thunoe R et al. - suPAR as a biomarker for risk stratification in the emergency department: A systematic review. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2022.
3. Hayek SS et al. - A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease. Nature Medicine, 2017.